Naquotinib | B1317

Naquotinib is a potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor that displays antineoplastic activity. Naquotinib preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.

Naquotinib is a potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor that displays antineoplastic activity. Naquotinib preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.

B1317 | Naquotinib DataSheet

Alternate Name/Synonyms: (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide; ASP8273

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 448232-80-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₀H₄₂N₈O₃

Molecular Weight: 562.72

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor

MDL Number: N/A

PubChem CID: 71667668

SMILES: CCC1=NC(=C(N=C1OC2CCN(C2)C(=O)C=C)NC3=CC=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)C(=O)N

InChi: CCC1=NC(=C(N=C1O[C@@H]2CCN(C2)C(=O)C=C)NC3=CC=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)C(=O)N

InChi Key: QKDCLUARMDUUKN-XMMPIXPASA-N